CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study aimed to identify the clinicopathological features of bladder cancer patients with high CD74 expression, as milatuzumab humanized anti-CD74 antibody is being evaluated in clinical trials for hematological malignancies. Expression of CD74 was examined in 342 urothelial carcinomas of the bladder, and two urothelial carcinoma cell lines by immunohistochemistry and western blotting, respectively. CD74 was overexpressed in 192 (56.1%) of the 342 cancer tissues, although it was not expressed in the cancer cell lines. CD74 staining was intense in tumor cells and inflammatory cells in the tumor stroma, but not in normal urothelium. CD74 expression was significantly associated with older age at diagnosis (≥68years, P=0.048), high World Health Organization grade (P=0.019), advanced stages (P=0.001) and non-papillary growth pattern (P=0.040). CD74 expression was also correlated with the absence of tumor-infiltrating inflammatory cells (P<0.001) and the presence of tumor-associated inflammatory cells (P=0.017). However, CD74 expression was not related to recurrence-free and overall survivals in primary and subgroup analyses. In conclusion, urothelial bladder carcinomas with high CD74 expression are characterized by older age, high World Health Organization grade, non-papillary growth and advanced stages.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalInternational Journal of Urology
Volume20
Issue number2
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Urinary Bladder
Carcinoma
Neoplasms
Antibodies, Monoclonal, Humanized
Cell Line
Urothelium
Hematologic Neoplasms
Growth
Urinary Bladder Neoplasms
Anti-Idiotypic Antibodies
Western Blotting
Immunohistochemistry
Clinical Trials
Staining and Labeling
Recurrence
Survival

Keywords

  • Bladder
  • CD74
  • Immunohistochemistry
  • Macrophage migration inhibitory factor receptor
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. / Choi, Jung-Woo; Kim, Younghye; Lee, Ju-Han; Kim, Young Sik.

In: International Journal of Urology, Vol. 20, No. 2, 01.02.2013, p. 251-255.

Research output: Contribution to journalArticle

@article{864469c9a1284cb48d6628d3633c8f2a,
title = "CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder",
abstract = "This study aimed to identify the clinicopathological features of bladder cancer patients with high CD74 expression, as milatuzumab humanized anti-CD74 antibody is being evaluated in clinical trials for hematological malignancies. Expression of CD74 was examined in 342 urothelial carcinomas of the bladder, and two urothelial carcinoma cell lines by immunohistochemistry and western blotting, respectively. CD74 was overexpressed in 192 (56.1{\%}) of the 342 cancer tissues, although it was not expressed in the cancer cell lines. CD74 staining was intense in tumor cells and inflammatory cells in the tumor stroma, but not in normal urothelium. CD74 expression was significantly associated with older age at diagnosis (≥68years, P=0.048), high World Health Organization grade (P=0.019), advanced stages (P=0.001) and non-papillary growth pattern (P=0.040). CD74 expression was also correlated with the absence of tumor-infiltrating inflammatory cells (P<0.001) and the presence of tumor-associated inflammatory cells (P=0.017). However, CD74 expression was not related to recurrence-free and overall survivals in primary and subgroup analyses. In conclusion, urothelial bladder carcinomas with high CD74 expression are characterized by older age, high World Health Organization grade, non-papillary growth and advanced stages.",
keywords = "Bladder, CD74, Immunohistochemistry, Macrophage migration inhibitory factor receptor, Urothelial carcinoma",
author = "Jung-Woo Choi and Younghye Kim and Ju-Han Lee and Kim, {Young Sik}",
year = "2013",
month = "2",
day = "1",
doi = "10.1111/j.1442-2042.2012.03128.x",
language = "English",
volume = "20",
pages = "251--255",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder

AU - Choi, Jung-Woo

AU - Kim, Younghye

AU - Lee, Ju-Han

AU - Kim, Young Sik

PY - 2013/2/1

Y1 - 2013/2/1

N2 - This study aimed to identify the clinicopathological features of bladder cancer patients with high CD74 expression, as milatuzumab humanized anti-CD74 antibody is being evaluated in clinical trials for hematological malignancies. Expression of CD74 was examined in 342 urothelial carcinomas of the bladder, and two urothelial carcinoma cell lines by immunohistochemistry and western blotting, respectively. CD74 was overexpressed in 192 (56.1%) of the 342 cancer tissues, although it was not expressed in the cancer cell lines. CD74 staining was intense in tumor cells and inflammatory cells in the tumor stroma, but not in normal urothelium. CD74 expression was significantly associated with older age at diagnosis (≥68years, P=0.048), high World Health Organization grade (P=0.019), advanced stages (P=0.001) and non-papillary growth pattern (P=0.040). CD74 expression was also correlated with the absence of tumor-infiltrating inflammatory cells (P<0.001) and the presence of tumor-associated inflammatory cells (P=0.017). However, CD74 expression was not related to recurrence-free and overall survivals in primary and subgroup analyses. In conclusion, urothelial bladder carcinomas with high CD74 expression are characterized by older age, high World Health Organization grade, non-papillary growth and advanced stages.

AB - This study aimed to identify the clinicopathological features of bladder cancer patients with high CD74 expression, as milatuzumab humanized anti-CD74 antibody is being evaluated in clinical trials for hematological malignancies. Expression of CD74 was examined in 342 urothelial carcinomas of the bladder, and two urothelial carcinoma cell lines by immunohistochemistry and western blotting, respectively. CD74 was overexpressed in 192 (56.1%) of the 342 cancer tissues, although it was not expressed in the cancer cell lines. CD74 staining was intense in tumor cells and inflammatory cells in the tumor stroma, but not in normal urothelium. CD74 expression was significantly associated with older age at diagnosis (≥68years, P=0.048), high World Health Organization grade (P=0.019), advanced stages (P=0.001) and non-papillary growth pattern (P=0.040). CD74 expression was also correlated with the absence of tumor-infiltrating inflammatory cells (P<0.001) and the presence of tumor-associated inflammatory cells (P=0.017). However, CD74 expression was not related to recurrence-free and overall survivals in primary and subgroup analyses. In conclusion, urothelial bladder carcinomas with high CD74 expression are characterized by older age, high World Health Organization grade, non-papillary growth and advanced stages.

KW - Bladder

KW - CD74

KW - Immunohistochemistry

KW - Macrophage migration inhibitory factor receptor

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84873270027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873270027&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2012.03128.x

DO - 10.1111/j.1442-2042.2012.03128.x

M3 - Article

C2 - 22905972

AN - SCOPUS:84873270027

VL - 20

SP - 251

EP - 255

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -